Inhalation delivery for the treatment and prevention of covid-19 infection

Basanth Babu Eedara, Wafaa Alabsi, David Encinas-Basurto, Robin Polt, Julie G. Ledford, Heidi M. Mansour

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Coronavirus disease-2019 (COVID-19) is caused by coronavirus-2 (SARS-CoV-2) and has produced a global pandemic. As of 22 June 2021, 178 million people have been affected worldwide, and 3.87 million people have died from COVID-19. According to the Centers for Disease Control and Prevention (CDC) of the United States, COVID-19 virus is primarily transmitted between people through respiratory droplets and contact routes. Since the location of initial infection and disease progression is primarily through the lungs, the inhalation delivery of drugs directly to the lungs may be the most appropriate route of administration for treating COVID-19. This review article aims to present possible inhalation therapeutics and vaccines for the treatment of COVID-19 symptoms. This review covers the comparison between SARS-CoV-2 and other coronaviruses such as SARS-CoV/MERS, inhalation therapeutics for the treatment of COVID-19 symptoms, and vaccines for preventing infection, as well as the current clinical status of inhaled therapeutics and vaccines.

Original languageEnglish (US)
Article number1077
JournalPharmaceutics
Volume13
Issue number7
DOIs
StatePublished - Jul 2021

Keywords

  • COVID-19
  • Clinical status
  • Inhalation delivery
  • Inhalation therapeutics
  • Respiratory vaccines

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Inhalation delivery for the treatment and prevention of covid-19 infection'. Together they form a unique fingerprint.

Cite this